Which statement is true of clients with ultra-metabolizing polymorphisms?

Individuals with ultra-metabolizing polymorphisms have genetic variations that lead to an increased activity of enzymes responsible for drug metabolism, particularly cytochrome P450 enzymes. This heightened enzymatic activity means that medications are processed and eliminated from the body more rapidly than usual.

As a result, clients with these polymorphisms may require higher doses of certain medications or may need to take medications more frequently to achieve the desired therapeutic effect. The lack of effective drug levels can lead to treatment failures if dosages are not properly adjusted.

Understanding the metabolism of these clients is crucial for personalized medicine and ensures that they receive adequate treatment for their conditions.